112 filings
Page 5 of 6
8-K
qhp 78zjg
8 Jan 18
Regulation FD Disclosure
12:00am
8-K
dg88k6uls1t2knufyjmk
4 Dec 17
Departure of Directors or Certain Officers
12:00am
8-K
kebt174ca3xljeas1
28 Nov 17
CytomX Therapeutics Announces FDA Acceptance of Investigational New Drug Application for CTLA-4 Probody Therapeutic
12:00am
8-K
yun3r3phlb wfpn5
7 Nov 17
CytomX Announces Third Quarter 2017 Financial Results and Operational Progress
12:00am
8-K
10jg0e652e2d6 mi
24 Oct 17
CytomX Therapeutics Appoints Charles S. Fuchs, M.D., MPH to
12:00am
8-K
6u2ze
3 Oct 17
Amgen and Cytomx Therapeutics Announce
12:00am
8-K
y7ipmvc28u26td0lxy
7 Aug 17
CytomX Announces Second Quarter 2017 Financial Results and Mid-Year Update Webcast Conference Call
12:00am
8-K
csv3ug
17 Jul 17
Changes in Registrant's Certifying Accountant
12:00am
8-K
ueryuklzs krh8xni
29 Jun 17
CytomX Achieves Development Milestone in Strategic Oncology Collaboration with AbbVie for CD71-Targeting Probody Drug Conjugate
12:00am
8-K
2bg1nw z89udn410
28 Jun 17
CytomX Announces the First Patient Treated in Phase 1/2 PROCLAIM-CX-2009 Trial
12:00am
8-K
6xd f3uvg
21 Jun 17
Submission of Matters to a Vote of Security Holders
12:00am
8-K
enyqgcl8
15 May 17
Departure of Directors or Certain Officers
12:00am
8-K
mrdjwb jzifnx56n
5 May 17
CytomX Announces First Quarter 2017 Financial Results
12:00am
8-K
tuepk8 7xevjru25x5f
30 Mar 17
CytomX Therapeutics Appoints Marion McCourt to Board of Directors
12:00am
8-K
w2ribfczng
20 Mar 17
Entry into a Material Definitive Agreement
12:00am
8-K
gaj9t83zu62ity
2 Mar 17
CytomX Announces Full-Year 2016 Financial Results
12:00am
8-K
riwq3fowm6
10 Jan 17
Results of Operations and Financial Condition
12:00am
8-K
e3o57je2e4 u5fjq4
14 Dec 16
CytomX Announces U.S. FDA Clearance of Investigational New Drug Application for Phase 1/2 Clinical Study of Anti-PD-L1 Probody Therapeutic, CX-072
12:00am
8-K
316zs44 wjm
13 Dec 16
CytomX Announces Selection by Bristol-Myers Squibb of First Clinical Candidate Probody From Collaboration
12:00am
8-K
4e1a6yke
5 Dec 16
CytomX Announces Fourth Target Selection by Bristol-Myers Squibb Under Strategic Oncology Collaboration
12:00am